Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C24H26N3O7S.Na |
| Molecular Weight | 523.534 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].COC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC(CC#CCN3CCOCC3)C([O-])=O
InChI
InChIKey=GTRATBLFFBCELU-UHFFFAOYSA-M
InChI=1S/C24H27N3O7S.Na/c1-33-20-9-5-18(6-10-20)23(28)25-19-7-11-21(12-8-19)35(31,32)26-22(24(29)30)4-2-3-13-27-14-16-34-17-15-27;/h5-12,22,26H,4,13-17H2,1H3,(H,25,28)(H,29,30);/q;+1/p-1
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C24H26N3O7S |
| Molecular Weight | 500.544 |
| Charge | -1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
PG-116800 is a member of the hydroxyproline-based hydroxamic acid class of matrix metalloproteinase (MMP) inhibitors. PG-116800 did not modify matrix structure in osteoarthritic patients. Also, it had unexpected side effects on muscle and skeleton; it limited joint mobility, and caused arthralgia, hand oedema, palmar fibrosis, Dupuytren’s contracture and persistent tendon thickness or nodules. PG-116800 failed to reduce left ventricular remodeling or improve clinical outcomes after myocardial infarction.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The quest for the Holy Grail: a disease-modifying osteoarthritis drug. | 2007 |
|
| Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. | 2007 |
|
| Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. | 2006-07-04 |
|
| Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. | 2006-06 |
|
| The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. | 2006-02-15 |
|
| Clinical trials update from the American College of Cardiology meeting: CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER. | 2005-08 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 20:23:10 GMT 2025
by
admin
on
Wed Apr 02 20:23:10 GMT 2025
|
| Record UNII |
ZG4GUS8D9F
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
171390223
Created by
admin on Wed Apr 02 20:23:10 GMT 2025 , Edited by admin on Wed Apr 02 20:23:10 GMT 2025
|
PRIMARY | |||
|
ZG4GUS8D9F
Created by
admin on Wed Apr 02 20:23:10 GMT 2025 , Edited by admin on Wed Apr 02 20:23:10 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|